New Formulations of Propafenone to Treat Atrial Fibrillation
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 193 participants.
Also called NCT02710669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 193 participants
- Registry
-
NCT02710669
-
- Other papers using this trial's data
- A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT02710669. Randomized; triple masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2020-03-11 (actual). Results posted on 2021-05-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- New Formulations of Propafenone to Treat Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- (R)-propafenone
- Intervention (Drug)
- (S)-Propafenone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Vanderbilt University
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct02710669- Content hash
96f9bcdfa2a51b60ff570c6ae9df6b1f65eccce4ffe0efc1cc5b694f9aa9354a